About Starton Therapeutics
Starton Therapeutics is a private company based in Paramus, New Jersey. It has reported $10,737,604 raised in nine offerings on Form D since July 2018.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Oct 10, 2024 | Oct 22, 2024 | $2,126,035fully sold | 16 | $132K | EquityRule 506(b) | Form D ↗ |
| Oct 1, 2023 | Oct 13, 2023 | $970,930fully sold | 8 | $121K | EquityRule 506(b) | Form D ↗ |
| Mar 31, 2023 | Apr 13, 2023 | $1,443,520fully sold | 7 | $206K | EquityRule 506(b) | Form D ↗ |
| Jan 18, 2023 | Jan 25, 2023 | $1,023,417fully sold | 11 | $93,038 | EquityRule 506(b) | Form D ↗ |
| Feb 11, 2022 | Feb 16, 2022 | $1,145,350fully sold | 9 | $127K | EquityRule 506(b) | Form D ↗ |
| Oct 19, 2021 | Nov 22, 2021 | $1,145,375fully sold | 39 | $29,369 | EquityRule 506(b) | Form D ↗ |
| Mar 3, 2021 | May 26, 2021 | $77,597fully sold | 5 | $15,519 | EquityRule 506(b) | Form D ↗ |
| Dec 20, 2019 | Jan 13, 2020 | $2,038,703target not set | 25 | $81,548 | EquityRule 506(b) | Form D ↗ |
| Apr 4, 2018 | Jul 2, 2018 | $766,677target not set | 15 | $51,112 | EquityRule 506(b) | Form D ↗ |
| Total, nine offerings | $10,737,604 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Starton Therapeutics's Form D filed Oct 22, 2024.
Earlier filings also listed Cidnee Vaykovich (chief operating officer, last listed Jan 2023), Pedro Waisman (executive officer and director, last listed Feb 2022), Keith Darragh (chief financial officer, last listed Feb 2022), Pedro Lichtinger (chief executive officer and director, last listed May 2021), Litsa Perperidis (promoter, last listed May 2021), Roy Waldon (director, last listed Jan 2020), Roman Rogol (director, last listed Jan 2020) and Nintin Kaushal (director, last listed Jul 2018).